Paper39799396
Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency.
Zhou J and 13 others. Mol Ther, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency. Papers, record 39799396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39799396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Characterization of a novel conditional knockout mouse model to assess efficacy of mRNA therapy in the context of severe OTC deficiency.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| RNA, Messenger | Major topic |
| Ornithine Carbamoyltransferase Deficiency Disease | Major topic |
| Ornithine Carbamoyltransferase | Major topic |
| Genetic Therapy | Major topic |
| Animals | |
| Mice | |
| Disease Models, Animal | |
| Mice, Knockout | |
| Nanoparticles | |
| Humans | |
| Tamoxifen |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25647322 | A new mouse model of mild ornithine transcarbamylase deficiency (spf-j) displays cerebral amino acid perturbations at baseline and upon systemic immune activation. | PLoS One | 2015 | https://conductscience.org/library/papers/25647322 | PubMed |
| 2 | 35211641 | Prednisolone reduces the interferon response to AAV in cynomolgus macaques and may increase liver gene expression. | Mol Ther Methods Clin Dev | 2022 | https://conductscience.org/library/papers/35211641 | PubMed |
| 3 | 9686344 | The biochemical and molecular spectrum of ornithine transcarbamylase deficiency. | J Inherit Metab Dis | 1998 | https://conductscience.org/library/papers/9686344 | PubMed |
| 4 | 29653760 | A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. | Mol Ther | 2018 | https://conductscience.org/library/papers/29653760 | PubMed |
| 5 | 28283349 | AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. | Mol Genet Metab | 2017 | https://conductscience.org/library/papers/28283349 | PubMed |
| 6 | 18562231 | Cross-sectional multicenter study of patients with urea cycle disorders in the United States. | Mol Genet Metab | 2008 | https://conductscience.org/library/papers/18562231 | PubMed |
| 7 | 15050978 | The role of liver transplantation in urea cycle disorders. | Mol Genet Metab | 2004 | https://conductscience.org/library/papers/15050978 | PubMed |
| 8 | 27860485 | An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease. | Expert Opin Drug Metab Toxicol | 2017 | https://conductscience.org/library/papers/27860485 | PubMed |
| 9 | 29511548 | Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis. | United European Gastroenterol J | 2018 | https://conductscience.org/library/papers/29511548 | PubMed |
| 10 | 22642880 | Suggested guidelines for the diagnosis and management of urea cycle disorders. | Orphanet J Rare Dis | 2012 | https://conductscience.org/library/papers/22642880 | PubMed |
| 11 | 481951 | Ornithine transcarbamylase deficiency in mutant mice I. Studies on the characterization of enzyme defect and suitability as animal model of human disease. | Pediatr Res | 1979 | https://conductscience.org/library/papers/481951 | PubMed |
| 12 | 16237708 | Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. | Liver Transpl | 2005 | https://conductscience.org/library/papers/16237708 | PubMed |
| 13 | 3162766 | Correction of mouse ornithine transcarbamylase deficiency by gene transfer into the germ line. | Nucleic Acids Res | 1988 | https://conductscience.org/library/papers/3162766 | PubMed |
| 14 | 33473356 | Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. | Mol Ther Methods Clin Dev | 2021 | https://conductscience.org/library/papers/33473356 | PubMed |
| 15 | 29433939 | Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. | Mol Ther | 2018 | https://conductscience.org/library/papers/29433939 | PubMed |
| 16 | 26059767 | Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. | J Genet Genomics | 2015 | https://conductscience.org/library/papers/26059767 | PubMed |
| 17 | 23430554 | Amino Acid Profiles in Patients with Urea Cycle Disorders at Admission to Hospital due to Metabolic Decompensation. | JIMD Rep | 2013 | https://conductscience.org/library/papers/23430554 | PubMed |
| 18 | 11124797 | Ornithine carbamoyltransferase deficiency. | Arch Dis Child | 2001 | https://conductscience.org/library/papers/11124797 | PubMed |
| 19 | 21376697 | Paediatric liver transplantation for metabolic disorders. Part 1: Liver-based metabolic disorders without liver lesions. | Clin Res Hepatol Gastroenterol | 2011 | https://conductscience.org/library/papers/21376697 | PubMed |
| 20 | 21376696 | Paediatric liver transplantation for metabolic disorders. Part 2: Metabolic disorders with liver lesions. | Clin Res Hepatol Gastroenterol | 2011 | https://conductscience.org/library/papers/21376696 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42398834 | New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics. | J Control Release | 2026 | https://conductscience.org/library/papers/42398834 | PubMed |
| 40976841 | Current Treatment Modalities for Urea Cycle Disorders. | Paediatr Drugs | 2025 | https://conductscience.org/library/papers/40976841 | PubMed |
| 39986270 | mRNA therapy as primary and bridge therapy for inborn errors of metabolism. | Mol Ther | 2025 | https://conductscience.org/library/papers/39986270 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39799396
GET https://conductscience.org/api/papers/v1/39799396/references?page=2